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A B S T R A C T
Background: The objective of this study was to assess treatment consumption and re-enrollment in treatment in
patients with gamma-hydroxybutyrate (GHB)-dependence in Dutch Addiction Treatment Centers (ATCs) in
comparison with other addictions.
Methods: A cohort-study using nationwide administrative data from regular Dutch ATCs associated with the
Dutch National Alcohol and Drugs Information System (LADIS), covering an estimated 95% of ATCs. We selected
in- and out-patients with alcohol, drug and/or behavioral addictions with a ﬁrst treatment episode in 2008–2011
and consecutive treatments until 2013 (n = 71,679). Patients still in treatment at that date (n = 3686; 5.1%),
forensic patients (n = 1949; 2.7%) and deceased patients (n = 570; 0.8%) were excluded, leaving 65,474
patients (91.3%). Of those, 596 (0.9%) patients had GHB dependence. We analyzed number of treatment
contacts, treatment duration, admissions and admission duration of the ﬁrst treatment episode, and re-
enrollment (deﬁned as having started a second treatment episode in the study period).
Results: GHB-dependent patients showed the highest number of treatment contacts, duration of treatment and
chance of being admitted. Re-enrollment rates were 2–5 times higher in GHB-dependent patients than other
patients with adjusted HR of other addictions ranging from 0.18 (95% conﬁdence interval [CI]: 0.15–0.21) to
0.53 (95% CI: 0.47–0.61).
Conclusions: This study demonstrates high levels of treatment consumption and high rates of treatment re-
enrollment in GHB-dependent patients. These ﬁndings highlight the urgency of developing eﬀective relapse
prevention interventions for GHB-dependent patients.
1. Introduction
Gamma-hydroxybutyrate (GHB) and its precursor gamma-butyro-
lactone (GBL) are popular drugs of abuse in several countries including
the Netherlands. Although originally developed as an anesthetic, due to
unpredictable side eﬀects like vomiting, medical use is nowadays
limited. As sodium oxybate, GHB is registered for treatment of
narcolepsy and, in some countries, for treatment of alcohol withdrawal
as well (Brunt et al., 2013a; Snead and Gibson, 2005). The well-
reported euphoric and sexually stimulating eﬀects of GHB have
facilitated its development as a party-drug. Prevalence estimates of
current GHB use in Australia, the United Kingdom and the Netherlands
range from 0.1% to 0.4% in the adult population, whereas rates among
regular nightclub attenders are considerably higher with a reported
current use prevalence of up to 10.5% (Corkery et al., 2015; van
Amsterdam et al., 2012; Van Laar et al., 2012).
Over the last decade, medical complications as a result of GHB
abuse have increased. In the Netherlands, Emergency Department (ED)
presentations have increased from 300 in 2004–1200 in 2009 (Brunt
et al., 2013a; Van Laar et al., 2012). Intoxications with GHB frequently
occur, because of its narrow therapeutic window and short plasma half-
life (van Amsterdam et al., 2012; Wood et al., 2011). Intoxications
usually result in coma and may even be fatal, especially in the case of
co-abuse of other sedative substances like alcohol (Corkery et al., 2015;
Knudsen et al., 2008; Zvosec et al., 2011).
The high addictive potential of GHB has been recognized only since
a decade (Snead and Gibson, 2005; van Amsterdam et al., 2012). In
accordance, since 2007 a marked increase in GHB-related treatment
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seeking has been noticed in Dutch addiction treatment centers (ATCs;
van Amsterdam et al., 2012). GHB users frequently report withdrawal
symptoms upon cessation of daily use of GHB. Regular GHB use may
result in tolerance and dependence in weeks, and many GHB-dependent
users report an ‘around the clock’ dosing pattern in which they need to
take doses every one or two hours as well as several nightly doses to
prevent withdrawal symptoms (McDonough et al., 2004; Tarabar and
Nelson, 2004; van Noorden et al., 2009). Abrupt decrease or disconti-
nuation of heavy GHB use may result in a severe and life-threatening
withdrawal syndrome characterized by autonomic instability, delirium
and aggression (McDonough et al., 2004; Snead and Gibson, 2005;
Tarabar and Nelson, 2004; van Noorden et al., 2009).
To date, studies that compare course and characteristics of GHB
dependence with other addictions are lacking. Treatment of GHB
dependence has neither been systematically investigated. Hence, no
international guidelines exist (de Jong et al., 2013). Nevertheless,
treatment of GHB dependence usually starts with inpatient detoxiﬁca-
tion due to the high level of physical dependence. Detoxiﬁcation with
benzodiazepines, the recommended treatment in most case reports and
reviews, often appears problematic due to benzodiazepine-resistance
(de Jong et al., 2012; McDonough et al., 2004; Sivilotti et al., 2001; van
Noorden et al., 2014; Wojtowicz et al., 2008).
For several years, in Dutch ATCs detoxiﬁcation with titration and
tapering using pharmaceutical GHB is common. Results in terms of
feasibility, eﬀectiveness and safety are promising (de Jong et al., 2012;
de Weert-van Oene et al., 2013; Dijkstra et al., 2016). However,
reported relapse-rates appear to be high: after 3 months of follow-up,
65% of patients had relapsed in GHB abuse (Dijkstra et al., 2016).
Since GHB dependence is a relatively new phenomenon, very little is
known about the course of GHB dependence, treatment eﬀectiveness,
and use of treatment facilities in addiction care. The high relapse rates
reported by clinicians indicate a possible under-treatment compared to
other addictions, that might be due to the complexity of GHB
dependence, like the high physical dependence, the narrow therapeutic
window and short plasma half-life, and the potentially life-threatening
withdrawal syndromes.
We used nationwide administrative data to investigate treatment
characteristics and separate treatment episodes in individual patients
and compared GHB-dependent patients with other drugs of abuse and
behavioral addictions. Under the assumption that re-enrollment in
treatment after a terminated treatment episode would be indicative of
a relapse in abuse, we studied re-enrollment in treatment: having
started a second treatment episode in the study period. We hypothe-
sized that, as compared with patients with other dependencies, treat-
ment-intensity in GHB-dependent patients would be higher since the
frequent need of inpatient detoxiﬁcation of these patients will likely
result in more treatment contacts and more ATC admissions. In
addition, we hypothesized that because of the high relapse rates
GHB-dependent patients more often had multiple treatment episodes
than patients dependent on other common drugs of abuse or behavioral
addictions.
2. Material and methods
2.1. Design and setting
We used administrative data of the Dutch National Alcohol and
Drugs Information System (LADIS). The LADIS has been founded in
1986 and includes outpatient and inpatient clinical treatment data of 11
large ATCs in the Netherlands, covering an estimated 95% of all
addiction treatments in the country (EMCCDA, 2015). Since 1994, all
patients entering regular Dutch addiction care receive an identiﬁcation
number in LADIS, allowing to identify ﬁrst and subsequent treatment
episodes of every individual patient. Since 2007, the LADIS identiﬁca-
tion number is based on the Citizen Service Number, a unique personal
number for everyone who is registered in Municipal Personal Records
Database in The Netherlands, minimizing the chance of duplicates in
the database. A preliminary report on the GHB treatment data of
2007–2010 has been previously published in a Dutch addiction journal
(Mol et al., 2014).
2.2. Participants
From 2008 to 2012 all 71,679 patients who initiated and completed
a ﬁrst treatment episode in regular Dutch ATCs associated with LADIS
were selected, according to the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) deﬁnition of ‘ﬁrst treatment’ (EMCDDA,
2012). Patients were followed until December 31st, 2013. Patients who
had not ended treatment by that time were excluded (n = 3686; 5.1%).
Since GHB was not registered as separate drug-class in forensic
addiction care (n = 1949; 2.7%), these patients were excluded from
analyses. In addition, we excluded patients who had deceased during
the ﬁrst treatment episode (n = 570; 0.8%). In total 65,474 patients
with a ﬁrst treatment episode in the study period were included for
analyses (91.3%). The following categories of primary addiction for
which treatment was initiated were considered and used in analyses:
GHB, cocaine, opioids, amphetamines, alcohol, cannabis, ecstasy,
medication, gambling and a rest-category consisting of other substances
as well as behavioral addictions like sexual addiction and game
addiction (‘other’). In addition, information on co-abuse was available
in LADIS, as well as the number of treatment contacts, number of ATC
admissions, duration of admission (length of hospitalization in ATC)
and duration of treatment. Available sociodemographic data included
gender, age, and ethnic background.
2.3. Re-enrollment deﬁnition
Re-enrollment in treatment was deﬁned as having started a second
treatment episode in the study period. A second treatment episode was
considered valid if the initiation date was after the recorded termina-
tion date of the ﬁrst treatment episode. If a recorded termination date of
the ﬁrst treatment episode was lacking, initiation of a second treatment
episode was deﬁned if the new date was at least 6 months after the
previous treatment contact. This is according to the international
standard of EMCDDA (EMCDDA, 2012). If a second treatment episode
had not started by December 31st, 2013, a single treatment episode was
recorded for this patient.
2.4. Statistical analyses
Using descriptive statistics, we summarized the sociodemographic
and clinical characteristics of primarily GHB-dependent patients and
patients with other addictions. We used the median and interquartile
range (IQR) in tables in case of skewed distributions. We used ANOVA
to compare number of treatment contacts, duration of treatment, being
admitted, and duration of admission between GHB and the other drugs
of abuse and behavioral addictions. With regard to re-enrollment, we
calculated several parameters. First, we calculated the proportion of
patients that re-enrolled in the study period: the re-enrollment propor-
tion. This proportion was the percentage of patients with more than one
treatment episode, in which the time factor was not taken into account.
The second parameter was the re-enrollment rate: after the ﬁrst
treatment episode, patients were followed until a next treatment
episode, or until the end of the study period. The re-enrollment rate
takes time at risk or person years (product of the number of patients and
follow-up time) into account, but not the fact that patients could get lost
to follow-up. The re-enrollment rate was calculated as follows: number
of patients with a second treatment episode × 100/sum of person
years, and can be interpreted as the number of patients per 100 that had
started a second treatment episode within one year after completing the
ﬁrst treatment episode. Third, we calculated the Hazard Ratios (HR) of
re-enrollment with Cox regression models, by using the time at risk. In a
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second Cox regression model, we adjusted for age, gender, ethnic
background and co-abuse. We present the unadjusted cumulative
incidence of re-enrollment (as% without re-enrollment) in Kaplan-
Meier survival curve, and the time in which 10% of the patients had
been re-enrolled (‘time to 10% re-enrollment’) from the survival table.
All analyses were performed with IBM SPSS Statistics Version 21.0.
3. Results
3.1. Treatment characteristics
GHB dependence was the primary reason for initiation of treatment
in 596 of 65,474 patients (0.9%) that had started a ﬁrst treatment
episode in Dutch addiction care in 2008–2011 and terminated treat-
ment at ultimately December 31st 2013. Median age of the GHB-
dependent patients was 25 years, 67% was male, and 89% had a Dutch
ethnic background (Table 1). Median age of the other patients was
signiﬁcantly higher with 35 years (F1,2 = 271.6, p < 0.001). Number
of treatment contacts and treatment duration were signiﬁcantly higher
in GHB-dependent patients as compared with the other drugs of abuse
and behavioral addictions (F1,9 = 46.7, p < 0.001 and F1,9 = 50.1,
p < 0.001, respectively; Table 1 and Fig. 1). Of all addictions, GHB
dependence most often resulted in admission in an ATC. (F1,9 = 106.3,
p < 0.001; Fig. 1). These ﬁndings were in line with our initial
hypothesis. Mean duration of admission in GHB-dependent patients
did not diﬀer from most other dependencies (Fig. 1).
3.2. Re-enrollment
Re-enrollment risks per primary substance use disorder or gambling
are presented in Table 2. As described before, re-enrollment was
deﬁned as having started a second treatment episode in the study
period. The re-enrollment proportion, i.e. the percentage of patients
that had re-enrolled, was 42.8 in GHB-dependent patients. Re-enroll-
ment proportions in other patient categories ranged from 10.2 to 28.8.
Per 100 GHB-dependent patients, 23.3 had re-enrolled per year (re-
enrollment rate), while for the other drugs of abuse or behavioral
addictions 3.8-11.0 had one re-enrollment per year. In an unadjusted
Cox regression model, the HR of re-enrollment per substance was
calculated with GHB as a reference. All other substances and gambling
demonstrated signiﬁcantly lower HRs for re-enrollment. In a second
Cox regression model, we adjusted for age, sex, co-abuse and ethnic
background. Again, GHB demonstrated the highest HR for re-enroll-
ment. Taking GHB as a reference, adjusted HRs for re-enrollment
ranged from 0.23 (95% CI 0.19–0.27) to 0.57 (95% CI 0.50–0.65).
Women had a lower HR for re-enrollment (0.91; 95%CI 0.87–0.94) as
compared with men, and patients with co-abuse had a higher HR for re-
enrollment (1.22; 95% CI 1.18–1.27) as compared with patients that
abused a single substance (data not presented in tables). The time to
10% re-enrollment was 99 days in GHB-dependent patients, and
189–923 days in the other patients.
Fig. 2 presents the Kaplan-Meier curves for the cumulative inci-
dence of re-enrollment (as percentage without re-enrollment, starting
with 100%) of GHB and the other drugs of abuse and behavioral
addictions. This ﬁgure illustrates the exceptionally high re-enrollment
rates in GHB dependence as compared with other addictions.
4. Discussion
GHB dependence has only recently gained clinical signiﬁcance,
reﬂected by the rapid increase in treatment-seeking in addiction care
over the past decade, and, as such, it is a relatively understudied
phenomenon. Very little is known about treatment eﬀectiveness and
use of treatment facilities in addiction care. This study used adminis-
trative data of 65,474 patients in regular Dutch addiction care to
compare GHB dependence with other drugs of abuse and behavioral
addictions in terms of treatment characteristics and re-enrollment rates.
We found that of all patients in addiction care, GHB-dependent patients
showed the highest treatment intensity, as indicated by high admission
rates, long admissions and high number of treatment contacts. In
addition, GHB-dependent patients had the highest risk of re-enrollment
into a new treatment episode in addiction care.
For a long time, the dependence liability of GHB was considered
low. Studies on medical use of GHB (e.g., sodium oxybate in narco-
lepsy) found abuse incidences of less than one percent (Wang et al.,
2009). Few studies in recreational GHB users indicated dependence
liability in frequent GHB users (Freese et al., 2002; Miotto et al., 2001).
By now, the dependence liability of GHB has been widely recognized
(Brunt et al., 2013a; Snead and Gibson, 2005; van Amsterdam et al.,
2012). In a study named ‘the Dutch GHB Monitor’, 274 patients with
GHB dependence have been followed during regular addiction treat-
ment including inpatient detoxiﬁcation from 2010 to 2012. Most
patients from the GHB Monitor have probably been included in the
LADIS database as well. After 3 months of follow-up, 65% of the
patients of the GHB monitor reported a relapse in GHB abuse (de Weert-
van Oene et al., 2013; Dijkstra et al., 2016). This percentage is
considerably higher than the re-enrollment rates we found in our study
and can be explained by the fact that relapses occurred during ongoing
treatment episodes (i.e. within 6 months after detoxiﬁcation). Further-
more, in this study we measured treatment re-enrollments (and not
relapse rates) after a terminated treatment episode. It can be hypothe-
sized that not every patient with a relapse will reinitiate treatment. For
Table 1
Sociodemographic and clinical characteristics per primary substance use disorder (or gambling) in a sample of 65,474 patients with ﬁrst treatment episode in Dutch addiction care in
2008–2012.
N Median Male Dutch Number of Treatment Duration Multiple
65,474 age gender background Treatment contacts 1 st episode, days substances
(IQR) (%) (n, %) (mean, SE) (median, IQR) (mean, SE) (median, IQR) abuse (n, %)
GHB 596 25 (21–30) 66.6 89.4 50.4 (3.62) 20 (7–51) 323.2 (13.52) 229 (90–430) 68.0
Cocaine 6479 29 (24–36) 82.2 64.3 29.0 (0.76) 11 (4–26) 257.9 (3.52) 169 (73–337) 61.6
Opioids 1627 36 (29–45) 77.8 29.0 32.3 (2.05) 10 (2–33) 314.6 (9.66) 169 (73–337) 44.2
Amphetamines 1626 23 (20–29) 71.9 80.0 31.8 (1.51) 11 (4–31) 279.1 (7.33) 186 (78–372) 62.5
Alcohol 31,87 44 (34–53) 69.2 68.4 26.3 (0.31) 11 (4–26) 270.7 (1.58) 186 (83–355) 27.0
Cannabis 15,879 23 (19–30) 77.0 63.6 22.1 (0.37) 10 (3–22) 230.8 (1.99) 155 (64–305) 33.4
Ecstasy 159 21 (18–29) 66.7 76.1 21.0 (3.09) 8 (3–23) 204.3 (18.25) 128 (57–255) 71.7
Gambling 3788 33 (25–43) 86.5 55.9 16.2 (0.54) 9 (4–17) 220.7 (3.74) 155 (74–291) 24.9
Medication 881 45 (36–54) 41.8 62.5 26.7 (1.41) 12 (4–30) 248.8 (9.32) 157 (60–330) 35.2
Other 2569 33 (22–45) 58.0 58.8 18.6 (0.85) 10 (3–23) 223.2 (4.73) 154 (64–292) 21.4
IQR denotes Interquartile Range; SE denotes Standard Error.
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published relapse rates of other drugs of abuse, we found the same
diﬀerence with relapse rates ranging from 40 to 60%, comparable with
other chronic diseases, which are notably higher than the re-enrollment
rates in our study (Hunt et al., 1971; McLellan et al., 2000; O’Brien
1997). Thus, using re-enrollment as a proxy for relapse is likely a
conservative approach for studying relapse rates. Given the profoundly
high re-enrollment rates in GHB-dependent patients as compared with
other drugs of abuse and behavioral addictions our ﬁndings are in line
with the ﬁndings of the GHB monitor and clinical experience that GHB
has high dependence liability with high relapse rates after detoxiﬁca-
tion. However, when interpreting this ﬁnding one has to keep in mind
that these administrative data on treatment intensity and treatment
Fig. 1. Means including Standard Errors of treatment characteristics per primary drug of abuse (or gambling) in 65,474 patients with a ﬁrst episode in Dutch addiction care from 2008 to
2011. The block size is indicative of the number of patients.
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characteristics lack details of the nature of treatment.
We were able to conﬁrm our hypothesis that GHB-dependent
patients showed the highest treatment intensity in terms of treatment
contacts and ATC admissions of all dependencies and behavioral
addictions in our study. In addition, if admitted, duration of admission
was higher in GHB-dependent patients as compared with other patients.
The high treatment intensity in GHB-dependent patients does not seem
to prevent high re-enrollment rates. Although our administrative data
did not include details of the treatment, we expect that, compared with
treatments for other dependencies, daily clinical treatment for GHB-
dependent patients is more focused on short-term outcomes (crisis
management).
This focus on short-term outcomes is in line with the particular
unpredictability of GHB, due to its narrow therapeutic window and
short plasma half-life, as well as potentially life-threatening withdrawal
syndromes, which play a more substantial role in GHB dependence than
in other substance dependencies. This unpredictability of GHB and the
frequent need for crisis management is conﬁrmed by the Dutch GHB
monitor in which one fourth of the admissions were emergency
admissions and in which 84% reported one or several comas, 43%
reported one or more ED admissions, and 20% reported one or more
Intensive Care Unit (ICU) admissions as a result of GHB use (de Weert-
van Oene et al., 2013; Dijkstra et al., 2016). The focus on short-term
outcome is also conﬁrmed by the high relapse rates immediately after
detoxiﬁcation (26.7%) which makes it hard to achieve proper diag-
nostics and appropriate follow-up management. Several Dutch studies
sought explanations for this high relapse and showed that anxiety,
cognitive problems, unsupportive living environments and lack of daily
activities are often mentioned as reasons for this fast relapse (Dijkstra
et al., 2013; Beurmanjer et al., 2016a; Beurmanjer et al., 2016b). The
lack of eﬀective relapse prevention strategies now often leave clinicians
empty-handed.
Our ﬁndings stress the importance of future studies on eﬀective
treatments of GHB dependence focusing on long-term outcomes besides
short-term outcomes, especially relapse prevention. Currently, trials are
being conducted in which baclofen will be studied in relapse prevention
(Lingford-Hughes et al., 2016; Kamal et al., 2015). Besides abstinence,
treatment goals focusing on stabilization should be considered to create
a basis for abstinence in the future.
This is the ﬁrst study that used administrative data to study
Table 2
Re-enrollment risks per primary substance use disorder (or gambling) in a sample of 65,474 patients with ﬁrst treatment episode in Dutch addiction care in 2008–2012.
N 65,474 Re-enrollment
(n)
Re-enrollment
proportiona (%)
Re-enrollment
rateb
HR re-enrollmentc
(95% CI)
Adjusted HR re-
enrollmentd (95% CI)
Time to 10% re-
enrollmente (days)
GHB 596 255 42.8 23.3 Ref Ref 99
Cocaine 6479 1867 28.8 11.0 0.53 (0.47–0.61)* 0.57 (0.50–0.65)* 189
Opioids 1627 444 27.3 11.0 0.53 (0.46–0.62)* 0.67 (0.57–0.78)* 147
Amphetamines 1626 392 24.1 9.3 0.45 (0.38–0.52)* 0.45 (0.38–0.52)* 246
Alcohol 31,870 6792 21.3 8.0 0.38 (0.34–0.43)* 0.53 (0.47–0.60)* 303
Cannabis 15,879 3303 20.8 7.7 0.37 (0.33–0.42)* 0.40 (0.35–0.45)* 324
Ecstasy 159 29 18.2 6.2 0.31 (0.21–0.45)* 0.30 (0.21–0.44)* 466
Gambling 3788 632 16.7 5.8 0.28 (0.25–0.33)* 0.35 (0.30–0.40)* 448
Medication 881 139 15.8 5.6 0.27 (0.22–0.34)* 0.40 (0.32–0.49)* 489
Other 2569 263 10.2 3.8 0.18 (0.15–0.21)* 0.23 (0.19–0.27)* 923
Re-enrollment indicates having started a second treatment episode in the study period. Ref denotes Reference.
a Re-enrollment proportion denotes the percentage of patients with re-enrollment.
b Re-enrollment-rate denotes the number of patients with re-enrollment × 100/sum of person-years (number of patients per 100 with re-enrollment each year). HR indicates Hazard
Ratio.
c HR of re-enrollment in Cox regression model.
d Adjusted for age, sex, co-abuse and ethnic background.
e Time to 10% relapse denotes the time in days after which 10% of the patients had re-enrolled.
* p < 0.001.
Fig. 2. Kaplan-Meier curves for the cumulative incidence of re-enrolment (displayed as% without re-enrolment in treatment) according to primary addiction in 65,474 patients with a ﬁrst
treatment episode in Dutch addiction care from 2008 to 2011. Re-enrolment was deﬁned as having started a second treatment episode in the study period that ended 31th December
2013. Time indicates follow-up time in years.
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treatment characteristics by means of treatment consumption para-
meters and re-enrollment rates. The large LADIS database with long-
itudinal data allowed us to compare GHB with the most common drugs
of abuse and behavioral addictions, providing robust results. The
estimated covering of 95% of Dutch addiction care treatments in
LADIS makes these results largely generalizable to clinical practice in
the Netherlands (EMCCDA, 2015).
Several potential limitations should be taken into account when
interpreting our results. First, the administrative and pseudonymized
data in LADIS prohibited us to directly investigate relapse-rates after
successful treatment as clinical chart-data about relapse was not
available. In addition, the administrative data was restricted to self-
reported primary drug of abuse and possible co-abuse, which we used in
our analyses. We were not able to clinically evaluate the primary reason
for seeking treatment, nor the importance of possible co-dependencies
or (mental) disorders (Brunt et al., 2013b). Second, patients who had
died during follow-up, patients who had moved to another country, or
patients who had started a second treatment episode in an ATC that is
not covered by LADIS, have been censored since follow-up information
about these patients was lacking. Third, we selected only patients with
a ﬁrst treatment episode in addiction care in the study period. This
allowed us to compare patients in the same treatment phase. In the
time-frame of the current study, the proportion of new GHB-dependent
patients was relatively high. For example, the re-enrollment rate of
patients with opioid dependence would have been 15.5 (instead of
10.5) if chronic patients would have been included as well. Never-
theless, in the latter case re-enrollment rates of GHB still would have
been much higher than all other drugs of abuse (27.1). Finally, since the
user-proﬁles of several dependencies show large diﬀerences (e.g., age
and socioeconomic status), comparing these groups is complicated.
Since characteristics like sociodemographic status were not available,
adjusting for known variables did not resolve this issue of matching.
5. Conclusions
GHB-dependent patients show high treatment consumption and
high treatment re-enrollment rates. These results stress the importance
of future studies on treatment of GHB use disorders, including relapse
prevention.
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